Risk factors
Kiniksa Pharmaceuticals International (KNSA) risk factors
Item 1A of every Kiniksa Pharmaceuticals International, plc 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors54 risks12 new18 dropped32 reworded
US ARCALYST remains the revenue base, while international expansion now carries explicit approval and commercialization uncertainty.
Filed Feb 24, 2026 - FY2024 10-K risk factors60 risks
Single-product commercialization reliance on ARCALYST drives primary risks, including sole-source manufacturing dependencies and complex intellectual property protection.
Filed Feb 25, 2025